IPO
-
-
-
-
-
-
-
Inhibikase Therapeutics (IKT) Reports First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson’s Disease and Related Disorders
-
-
-
-
122,349 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

